Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.



Cogstate tasks, including the Cogstate Brief Battery™, have been included in published studies across various indications.

Use the fields on the left to search specific areas of interest, including sensitivity in Alzheimer’s disease, Depression, Concussion/Athletes, AIDS/HIV, Schizophrenia, ADHD and Alcohol; as well as properties, demographic features and cultural validity.

Latest Publications

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.

Authors: Blennow K, Fuchs D, Gisslén M, Mellgren Å, Nilsson S, Yilmaz A, Zetterberg H

Journal: Infectious diseases

DOI: 10.1080/23744235.2019.1670352

Year Published: 2019

Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because of its low cerebrospinal fluid (CSF) concentrations and because it is a substrate of the active efflux transporter P-glycoprotein. Our aim […]

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer’s disease and mild cognitive impairment.

Authors: Chandra A, Cousins O, Dervenoulas G, Pagano G, Politis M, Valkimadi PE

Journal: Human brain mapping

DOI: 10.1002/hbm.24782.

Year Published: 2019

Alzheimer’s disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising […]

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

Authors: Gervasi L, McGowan T, Mehlhaff B, Pei H, Phillips J, Saltzstein D, Shore ND, Sieber P, Wong YN

Journal: Clinical genitourinary cancer

DOI: 10.1016/j.clgc.2019.07.017

Year Published: 2019

BACKGROUND: The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). PATIENTS AND METHODS: This was a phase IV, prospective, open-label, multicenter, real-world study. Patients were prescribed ENZA or AA+P at the treating physician’s discretion. Computerized tests […]

How can we help optimize your study endpoints?

Please fill out the form below to get in touch